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ACEI = angiotensin-enzyme
converting inhibitor
ARB = angiotensin receptor
blocker
CI = conﬁdence interval
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HF-PEF = heart failure with
preserved ejection fraction
HF-REF = heart failure with
reduced ejection fraction
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quality of life
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LVEF = left ventricular
ejection fraction
MLwHF = Minnesota Living
with Heart Failure
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1846describing the symptom burden,
quality of life, and hospitaliza-
tion and mortality rates in HF
patients ages 20 to 60 years,
although it is in these patients
where estimates of prognosis
may be most keenly sought
by patients and their families.See page 1855Additionally and related to the
latter, the most invasive and
expensive therapeutic interven-
tions are most commonly con-
sidered for younger patients
(7,8). Consequently, knowledge
of the causes, characteristics,
and consequences of HF in
young patients is clinically im-
portant. We therefore analyzed
the CHARM (Candesartan in
Heart Failure Assessment of
Reduction in Mortality and mor-bidity programme) study database to provide a comprehen-
sive description of HF in younger patients, comparing them
with older participants.
The CHARM programme enrolled a broad spectrum of
patients with chronic HF who were 18 years or older.
Detailed information was collected on symptoms, signs,
quality of life, treatment, precipitants of hospitalization, and
nonfatal and fatal outcomes.
Methods
The rationale, design, and baseline characteristics of patients
in the CHARM programme and the primary analyses have
been published in detail elsewhere (9–14). Patients with
symptomatic HF (New York Heart Association [NYHA]
classes II to IV) for at least 4 weeks, who were 18 years or older
and receiving standard therapy (beta-blockers, diuretics, digi-
talis, and spironolactone), were enrolled into 1 of 3 parallel
clinical trials according to left ventricular ejection fraction
(LVEF) and angiotensin-converting enzyme inhibitor (ACEI)
treatment: LVEF 40% and not receiving an ACEI due to
previous intolerance (CHARM-Alternative); LVEF 40%
receiving ACEI treatment (CHARM-Added), and LVEF
>40% (CHARM-Preserved). Exclusion criteria included
serum creatinine265 mmol/l, serumpotassium5.5mmol/l,
knownbilateral renal artery stenosis, symptomatic hypotension,
women of childbearing age potentially not using adequate
contraception, critical aortic and mitral stenosis, myocardial
infarction, stroke, or open heart surgery in the previous 4weeks,
use of angiotensin-receptor blocker (ARB) in the previous
2 weeks, any noncardiac disease judged likely to limit 2-year
survival, and unwillingness to consent. All participatingcenters received approval from local ethics committees, and
all patients gave written consent before enrollment.
Between March 1999 and March 2001, 7,599 patients
(3,803 on candesartan, 3,796 on placebo) were randomized
to candesartan 4 or 8 mg once daily or matching placebo.
The dosage was doubled every 2 weeks, as tolerated, to
a target dose of 32 mg once daily, with recommended
monitoring of blood pressure, serum potassium, and creat-
inine. Visits were scheduled for every 4 months for a
minimum duration of 2 years after the initial dose titration.
The program was concluded, as planned, 2 years after the
ﬁnal patient was randomized, with a median duration of
follow-up of 37.7 months.
The present analysis groups patients into 5 age categories:
20 to 39 years (n ¼ 120), 40 to 49 years (n ¼ 538), 50 to 59
years (n ¼ 1,527), 60 to 69 years (n ¼ 2,395), and 70 years
(n ¼ 3,019). The investigator-reported primary etiology of
HF was systematically collected using a case report form that
consisted of 8 options (ischemic heart disease, idiopathic-
dilated cardiomyopathy [IDCM], hypertension, valvular
heart disease, diabetes mellitus, alcohol-related, atrial
ﬁbrillation, and other). Adherence to study drug was
assessed at each follow-up visit. At each visit, investigators
assessed adherence based on the patient’s report, the inves-
tigator’s inspection of pill bottles, and a tablet count in cases
of uncertainty. The investigators were asked to estimate
compliance with study drug by selecting 1 of the pre-deﬁned
categories (>80%, 20% to 80%, and <20% adherence) on
the case report form. We calculated adherence as the number
of visits when pills were taken as prescribed >80% of the
time divided by the number of visits actually made  100
(15). Patients recruited at the 243 sites in the United States
and Canada were prospectively asked to participate in the
CHARM Health-Related Quality of Life (HRQL) study.
Enrolled patients completed the Minnesota Living with
Heart Failure (MLwHF) questionnaire at baseline. The
questionnaire contains 21 disease-speciﬁc items, with a score
for each item ranging from 0 to 5 and a summary score of
0 to 105 (higher score represents worse quality of life). Data
regarding acute episodes of decompensation after rando-
mization were prospectively collected using a speciﬁcally
designed endpoint form documenting evidence of worsening
HF, precipitating or aggravating factors, and intravenous
treatment.
Baseline characteristics are reported as mean  SD for
continuous variables and proportions for categorical variables.
Variables were compared across age categories using analysis
of variance for continuous variables and chi-square or Fisher
exact tests for categorical variables. A conservative signiﬁ-
cance level of p < 0.0001 was adopted for the comparison of
baseline characteristics, given the retrospective nature of
the study and the multiple comparisons made. All-cause
mortality (the primary endpoint of the overall program),
the composite endpoint of cardiovascular death or HF
hospitalization (the primary outcome of the 3 component
trials), and the secondary pre-speciﬁed endpoints were
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1847analyzed by age group. Kaplan-Meier survival curves were
plotted by age category, and event-free survival was estimated
at 1, 2, and 3 years. Cox’s proportional hazard models were
used to estimate the hazard of younger age compared with
the age group of 60 to 69 years as the referent category,
adjusted for the previously published predictors of mortality
and morbidity speciﬁc to each endpoint in the CHARM trial
(16). For the survival analyses and multivariable models,
a conventional level of signiﬁcance was used (p < 0.05), and
the results are presented with 95% conﬁdence intervals (CIs).Results
Demography, etiology, and ejection fraction. Baseline
characteristics stratiﬁed by age are presented in Table 1.
Younger patients were less often of European origin (youn-
gest vs. oldest: 73% vs. 95%, p < 0.0001), but more often of
black ethnicity (18% vs. 2%, p < 0.0001), had a higher body
mass index (29.8 kg/m2 vs. 27.0 kg/m2, p < 0.0001) and
were more likely to be obese (body mass index 35 kg/m2:
23% vs. 6%, p < 0.0001). All age groups were predominantly
male, with the proportion of females increasing with age,
especially in the oldest age group (71%, 77%, 76%, 71%, and
61% male in age groups 20 to 39, 40 to 49, 50 to 59, 60 to
69 years, and 70 years, respectively, p < 0.0001).
In the youngest age group, the most common
investigator-reported etiology of HF was IDCM, followed
by a presumed ischemic etiology and hypertension. The
proportion of patients with a presumed ischemic and
hypertensive etiology increased progressively with age
(ischemic from 15% to 66% and hypertensive from 5% to
15%), comparing youngest and oldest patients, respectively
(p < 0.0001). The relative proportion of patients with
IDCM declined with age, from 62% in those ages 20 to 39
years to 9% in those ages 70 years (p < 0.0001). Alcohol-
related HF was more common in the youngest age group
than in the oldest age group (3% vs. 0%, p < 0.0001).
The mean ejection fraction was lowest in the youngest age
group and increased steadily with age (34%, 37%, 38%, 38%,
and 40% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69,
and 70 years, respectively; p < 0.0001). Across the same
age bands, the prevalence of HF with reduced ejection
fraction (HF-REF) (LVEF 40%) was greatest in young
patients and declined with age (70%, 66%, 64%, 63%, and
55%, respectively; p < 0.0001).
Comorbidities. Myocardial infarction, angina, stroke,
hypertension, diabetes, atrial ﬁbrillation, previous coronary
revascularization, and a pacemaker were less common in
younger patients and increased in prevalence with advancing
age (all p < 0.0001) (Table 1). The prevalence of a previous
HF hospitalization was similar in all age categories, likely
reﬂecting the inclusion criteria in CHARM Added (patients
in NYHA class II required hospitalization for a cardiac
condition within the past 6 months) and CHARM
Preserved (patients required previous hospitalization for
a cardiac condition at any time). The prevalence of smokingpeaked in the age group 40 to 49 years (30%) and declined
thereafter (8% in the elderly).
Symptoms and signs. The association between age and
present symptoms (i.e., at randomization) was inconsistent
(Table 2). In the youngest patients, dyspnea on level ground
was less frequent (45% <40 years vs. 68% in 70 years,
p < 0.0001), yet paroxysmal nocturnal dyspnea was more
prevalent (22% <40 years vs. 12% 70 years, p ¼ 0.001).
The prevalence of dyspnea at rest, dyspnea on climbing, and
orthopnea was similar across all age categories. The youngest
patients reported the worst quality of life scores, which
improved with increasing age (mean MLwHF scores 52.6,
50.8, 47.1, 38.9, and 35.3 in age groups 20 to 39, 40 to 49,
50 to 59, 60 to 69, and 70 years, respectively; p < 0.0001).
Past signs and present signs (i.e., reported before and at the
time of randomization) were consistent. The prevalence of
jugular venous pressure elevation was similar across age
categories. An S3 gallop and hepatomegaly were more
common in younger patients (youngest vs. oldest patients: S3
gallop 46% vs. 20% previously and 31% vs. 11% at
randomization; hepatomegaly 28% vs. 14% previously and
10% vs. 7% at randomization; all p < 0.0001). In contrast,
signs of ﬂuid extravasation (peripheral edema and basilar
pulmonary crackles) were less common in the younger
patients. Systolic blood pressure was lowest and mean heart
rate highest in younger patients (121 mmHg vs. 134 mmHg
and 78 beats/min vs. 72 beats/min comparing those ages<40
years against those ages 70 years, respectively, p < 0.0001).
Investigations. A normal electrocardiogram was uncom-
mon, irrespective of age (9% vs. 8% youngest vs. oldest)
(Table 3). Speciﬁc abnormalities were signiﬁcantly less
common in younger patients and increased with age,
including atrial ﬁbrillation or ﬂutter (4% vs. 20%), bundle
branch block (22% vs. 26%), paced rhythm (1% vs. 10%),
and pathological Q waves (10% vs. 23%) (all p < 0.0001).
The exception was left ventricular hypertrophy, which
occurred most frequently in the youngest age group (24% vs.
15%, p ¼ 0.032).
Radiological changes at randomization were uncommon.
Previous radiological abnormalities, however, exhibited
a similar pattern to clinical signs (Table 3). Cardiomegaly
was more common and ﬂuid extravasation was less common
in the young (interstitial pulmonary edema 20% vs. 28%,
bilateral effusions 6% vs. 19%; p < 0.0001). Mean sodium,
potassium, urea, and creatinine levels were lower in younger
patients, whereas the mean hemoglobin, white cell, and
platelet count were higher.
Medications. Compared with the oldest patients, the
youngest patients were more likely to receive an ACEI
(53% vs. 35%, p < 0.0001), a beta-blocker (62% vs. 48%,
p < 0.0001), spironolactone (20% vs. 17%, p ¼ 0.097), and
digoxin (64% vs. 42%, p < 0.0001) (Table 1). Diuretic use
was lowest in those ages 40 to 49 years and increased with
age (80%, 77%, 78%, 82%, and 87% in age groups 20 to 39,
40 to 49, 50 to 59, 60 to 69, and 70 years, respectively;
p< 0.0001). These overall percentages might be confounded
Table 1 Baseline Characteristics Stratiﬁed by Age
Age Groups (yrs)
20–39
(n ¼ 120)
40–49
(n ¼ 538)
50–59
(n ¼ 1,527)
60–69
(n ¼ 2,395)
70
(n ¼ 3,019) p Value
Male 71 77 76 71 61 <0.0001
Ethnicity European 73 82 86 91 95 <0.0001
Ethnicity black 18 10 6 4 2 <0.0001
Body mass index (kg/m2) 29.8  7.3 30.7  6.6 29.6  5.9 28.4  5.1 27.0  4.7 <0.0001
Body mass index (kg/m2)
<22.5 13 7 8 10 16 <0.0001
22.5–24.9 13 10 12 17 21
25.0–29.9 37 35 38 42 41
30.0–34.9 15 27 26 22 17
35.0 23 21 16 10 6
HF-REF vs. HF-PEF
EF (%) 34 (14) 37 (14) 38 (14) 38 (15) 40 (15) <0.0001
HF-REF (EF 40%) 70 66 64 63 55 <0.0001
HF-PEF (EF >40%) 30 34 36 37 45 <0.0001
Primary etiology (%)
Ischemic heart disease 15 45 58 65 66 <0.0001
Idiopathic dilated
cardiomyopathy
62 35 24 17 9 <0.0001
Hypertension 5 12 11 12 15 <0.0001
Valvular heart disease 3 2 1 2 3 0.001
Alcohol-related 3 2 2 1 0 <0.0001
Atrial ﬁbrillation 1 1 2 2 3 <0.0001
Medical history (%)
Previous HF hospitalization 83 71 71 71 71 0.257
Myocardial infarction 16 43 51 55 55 <0.0001
Angina (present) 5 19 24 25 24 <0.0001
Stroke 3 6 6 9 11 <0.0001
Hypertension 26 48 52 56 58 <0.0001
Diabetes mellitus 15 24 30 32 26 <0.0001
Atrial ﬁbrillation 13 13 19 26 36 <0.0001
CABG 4 14 21 27 25 <0.0001
PCI 8 19 20 17 14 <0.0001
Permanent pacemaker 3 4 5 7 12 <0.0001
Current smoker 26 30 23 15 8 <0.0001
Medications (%)
ACE inhibitor 53 48 47 43 35 <0.0001
Beta-blocker 62 63 63 57 48 <0.0001
Spironolactone 20 19 15 17 17 0.097
Digitalis 64 46 43 43 42 <0.0001
Diuretics 80 77 78 82 87 <0.0001
Medications (EF 40%) (%)
ACE inhibitor 69 64 62 57 49 <0.0001
Beta-blocker 66 63 63 56 48 <0.0001
Spironolactone 27 24 19 21 19 0.073
Digitalis 71 58 54 53 50 <0.0001
Diuretics 82 85 85 88 91 <0.0001
Adherence measure (%)
Adherence to study drug 80 87 89 90 88 0.001
Values are % or mean  SD.
ACE ¼ angiotensin converting enzyme; CABG ¼ coronary artery bypass grafting; EF ¼ ejection fraction; HF ¼ heart failure; PCI ¼ percutaneous coronary
intervention; PEF ¼ preserved ejection fraction; REF ¼ reduced ejection fraction.
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However, similar therapeutic trends occurred comparing the
youngest patients with oldest patients in HF-REF alone:
ACEI (69% vs. 49%, p < 0.0001), beta-blockers (66% vs.48%, p < 0.0001), spironolactone (27% vs. 19%, p ¼ 0.073),
and digoxin (71% vs. 50%, p < 0.0001).
Adherence measure. Adherence to study drug was the
lowest in the youngest age group (80%, 87%, 89%, 90%,
Table 2 Symptoms and Signs Stratiﬁed by Age
Age Groups (yrs)
20–39
(n ¼ 120)
40–49
(n ¼ 538)
50–59
(n ¼ 1,527)
60–69
(n ¼ 2,395)
70
(n ¼ 3,019) p Value
NYHA class
II 53 49 48 46 42 <0.0001
III 45 49 50 52 55
IV 2 2 2 3 3
Minnesota score
Mean  SD 52.6  27.6 50.8  24.9 47.1  24.3 38.9  23.9 35.3  21.6 <0.0001
Median (IQR) 61.0 (28.0–73.0) 51.5 (32.5–72.0) 48.0 (28.0–65.0) 38.0 (18.0–58.0) 33.0 (18.0–50.0) <0.0001
Past symptoms
Dyspnea at rest 62 53 48 47 49 0.009
Dyspnea on ﬂat 80 75 77 73 72 0.004
Dyspnea on climbing 79 78 78 76 72 <0.0001
Orthopnea 67 51 49 49 47 0.001
Paroxysmal nocturnal dyspnea 63 46 43 40 38 <0.0001
Present symptoms
Dyspnea at rest 11 12 11 11 11 0.898
Dyspnea on ﬂat 45 59 60 63 68 <0.0001
Dyspnea on climbing 93 90 92 91 91 0.790
Orthopnea 26 22 20 19 21 0.086
Paroxysmal nocturnal dyspnea 22 17 13 13 12 0.001
Heart rate and BP
Heart rate (beats/min) 78  12 76  14 74  14 72  13 72  13 <0.0001
Systolic BP (mm Hg) 121  17 126  18 128  18 130  19 134  19 <0.0001
Diastolic BP (mm Hg) 78  10 79  11 78  10 77  11 75  11 <0.0001
Pulse pressure (mm Hg) 43  13 46  12 50  14 54  15 59  16 <0.0001
Past signs
Jugular venous pressure >6 cm 36 27 28 25 26 0.038
Hepatomegaly 28 26 21 17 14 <0.0001
Peripheral edema 53 49 50 51 54 0.039
Basilar pulmonary crackles 49 43 47 51 54 <0.0001
S3 gallop 46 33 27 23 20 <0.0001
Present signs
Jugular venous pressure >6 cm 10 9 9 9 10 0.719
Hepatomegaly 10 14 13 11 7 <0.0001
Peripheral edema 19 21 24 26 30 <0.0001
Basilar pulmonary crackles 8 12 12 14 19 <0.0001
S3 gallop 31 15 12 12 11 <0.0001
Values are %, mean  SD, or median (interquartile range [IQR]).
BP ¼ blood pressure; NYHA ¼ New York Heart Association.
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and 70 years, respectively; p ¼ 0.001).
Heart failure hospitalization after randomization. Patients
ages 40 to 59 years had the lowest HF hospitalization rate
at 1, 2, and 3 years (Table 4). The youngest patients
had similar HF hospitalization rates to the oldest patients
(20 to 39 years vs. 70 years: 1 year, 15% vs. 14%; 2 years,
20% vs. 22%; 3 years, 24% vs. 28%). HF hospitalization
rates at 3 years were 24%, 15%, 15%, 22%, and 28% in ages
20 to 39, 40 to 49, 50 to 59, 60 to 69, and 70 years,
respectively. Younger patients were more likely to present
with exertional dyspnea, orthopnea, nocturnal dyspnea, and
fatigue at the time of HF hospitalization. As with clinical
signs and past investigations, pulmonary edema and radio-
logical signs of HF were again less common in younger
patients (youngest vs. oldest 24% vs. 35% and 28% vs. 53%,
respectively).Lifestyle factors were often thought to have contributed to
HF hospitalization in younger patients, who were 2 to 3
times less likely to adhere to their medications and dietary
restrictions. Comparing youngest patients (20 to 39 years)
with oldest patients (70 years), medication nonadherence
was 24% vs. 7% (p ¼ 0.001), dietary adherence was 21% vs.
9% (p ¼ 0.002), and reported alcohol excess was 3% vs. 1%
(p < 0.0001). No signiﬁcant difference was observed among
age groups in acute treatment with intravenous diuretics,
inotropes, or vasodilators.
Mortality and cardiovascular outcomes. Crude mortality
for any cause at 3 years was lowest in the youngest age
group and increased with age, although only markedly
above 60 years (12%, <40 years; 13%, 40 to 49 years; 13%,
50 to 59 years; 19%, 60 to 69 years; and 31%, 70 years;
p < 0.0001) (Fig. 1, Table 5). This remained the case after
adjusting for previously published predictors of mortality
Table 3 Investigative Findings Stratiﬁed by Age
Age Groups (yrs)
20–39
(n ¼ 120)
40–49
(n ¼ 538)
50–59
(n ¼ 1,527)
60–69
(n ¼ 2,395)
70
(n ¼ 3,019) p Value
Electrocardiogram
Normal 9 12 13 9 8 <0.0001
Atrial ﬁb/ﬂutter 4 7 11 14 20 <0.0001
Bundle branch block 22 17 22 25 26 <0.0001
Paced rhythm 1 3 3 5 10 <0.0001
Pathological Q waves 10 26 27 28 23 <0.0001
Left ventricular hypertrophy 24 17 16 16 15 0.032
Other abnormality 53 46 42 41 42 0.051
Chest x-ray
Interstitial pulmonary edema 20 18 22 24 28 <0.0001
Bilateral effusion 6 7 11 13 19 <0.0001
Cardiomegaly 51 39 39 37 39 0.020
Ejection fraction (%) 34 (14) 37 (14) 38 (14) 38 (15) 40 (15) <0.0001
Biochemistry
Sodium (mmol/l) 139.5  3.7 139.5  3.4 140.2  2.8 140.4  2.9 140.5  3.1 <0.0001
Potassium (mmol/l) 4.3  0.5 4.3  0.5 4.3  0.4 4.4  0.5 4.4  0.4 <0.0001
Urea (mg/dl) 14.7  6.8 17.2  14.9 16.6  11.4 18.6  12.5 19.8  13.1 <0.0001
Creatinine (mg/dl) 1.0  0.3 1.1  1.6 1.1  0.4 1.2  0.4 1.3  0.7 <0.0001
Hematological
Hemoglobin (g/dl) 14.2  1.5 14.1  1.6 13.9  1.5 13.6  1.7 13.3  1.6 <0.0001
White cell count (103/mm3) 7.6  2.5 7.9  2.4 7.5  2.1 7.3  2.1 7.2  2.3 0.001
Platelet count (103/mm3) 223.2  105.4 192.8  127.1 171.7  132.7 150.7  126.4 130.8  114.5 <0.0001
Mean corpuscular volume (mm3) 89.0  5.9 89.9  5.3 91.5  5.3 92.0  6.1 92.6  6.0 <0.0001
Values are % or mean  SD.
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pean origin, black, South Asian, Arab/Middle Eastern,
Oriental, Malay, or other) and the patients’ geographic
regions into the model made little difference to the
adjusted outcomes, and there was no interaction between
age and ethnicity (p ¼ 0.71) or age and regions (p ¼ 0.28).
The respective hazard ratios [HR] for ages <40, 40 to 49,
and 50 to 59 years, referenced to 60 to 69 years, were 0.60
(95% CI: 0.36 to 1.00; p ¼ 0.049), 0.63 (95% CI: 0.50 to
0.81; p < 0.0001), and 0.64 (95% CI 0.54 to 0.75;
p < 0.0001) for all-cause mortality. For cardiovascular
death, the HRs were 0.71 (95% CI: 0.42 to 1.18;
p ¼ 0.186), 0.78 (95% CI: 0.60 to 1.00; p ¼ 0.054), and
0.70 (95% CI: 0.59 to 0.84; p < 0.0001).
The relation between the HR for cardiovascular death or
HF hospitalization and age was nonlinear. The youngest age
group had a similar risk of cardiovascular death or HF
hospitalization compared with the referent age group of 60
to 69 years (HR: 0.99, 95% CI: 0.71 to 1.38; p ¼ 0.930).
This was driven by the aforementioned higher risk of HF
hospitalization in the youngest age group (Fig. 2). However,
the absolute number of events in this group was small,
resulting in wide CIs.
Discussion
With nearly 2,200 patients younger than 60 years (and
almost 660 younger than 50 years), we demonstrated some
striking differences from older patients with HF, in termsof demographics, etiology, comorbidity, symptoms, signs,
quality of life, investigative ﬁndings, treatment adherence,
potential precipitants of decompensation, and nonfatal and
fatal outcomes. We are not aware of any similarly compre-
hensive study of younger patients with HF.
That more younger patients were black is consistent
with epidemiological studies in the United States showing
that African Americans have a higher risk of developing
HF than do whites, and do so at an earlier age (17).
Similarly, the ﬁnding that a higher proportion of younger
patients had an investigator-reported etiology of IDCM
(and a smaller proportion of ischemic etiology) is consistent
with the occurrence of symptomatic coronary heart disease
later in life (2,18). Previous clinical trials (19–22) and
surveys and/or registries (6,23,24) reported a higher
proportion of IDCM in younger patients with HF. Inter-
pretation of this apparent association between age and
etiology requires consideration of both the numerator and
denominator. The incidence and prevalence of IDCM
increase steadily with age in the general population (25,26).
However, the incidence and prevalence of the 2 most
common alternative etiologies (ischemia and hypertension)
rise even more rapidly with age, thus diminishing the
relative frequency of IDCM in patients with an established
diagnosis of HF.
The lower prevalence of all comorbidities, including
diabetes mellitus, hypertension, and stroke, likewise reﬂects
these conditions occurring beyond middle age (2,6,27).
Because comorbidities (along with age) are among the most
Table 4
Clinical Presentation, Precipitating Factors, and Treatment Related to Unplanned Hospitalization for Heart Failure Occurring
After Randomization
Age Groups (yrs)
20–39
(n ¼ 120)
40–49
(n ¼ 538)
50–59
(n ¼ 1,527)
60–69
(n ¼ 2,395)
70
(n ¼ 3,019) p Value
Hospitalization rates, % (95% CI)
1 yr 15 (9–22) 8 (6–11) 7 (6–8) 11 (10–12) 14 (13–15) <0.0001
2 yrs 20 (12–27) 12 (9–15) 12 (10–13) 18 (16–19) 22 (20–23) <0.0001
3 yrs 24 (17–32) 15 (12–18) 15 (13–17) 22 (20–24) 28 (27–30) <0.0001
Hospital stay
Bed days, median (IQR) 12 (6–33) 8 (4–21) 10 (4–21) 12 (6–25) 11 (5–21) 0.007
Clinical presentation
Increasing dyspnea on exertion 93 92 85 86 82 0.016
Orthopnea 62 52 58 48 48 0.018
Nocturnal dyspnea 48 48 42 36 36 0.051
Increasing peripheral edema 41 51 52 46 45 0.052
Increasing fatigue or decreasing exercise tolerance 62 66 60 54 51 0.005
Renal hypoperfusion 7 11 18 20 20 0.051
Clinical pulmonary edema 24 19 32 35 35 0.022
Radiological sign of heart failure 28 43 46 48 53 0.005
Precipitating factors
Nonadherence with cardiac medications 24 13 15 7 7 0.001
Excessive salt intake/ dietary nonadherence 21 24 17 12 9 0.002
Alcohol excess 3 4 4 1 1 <0.0001
Inappropriate decrease of antifailure therapy 7 5 3 6 6 0.055
Cardiac arrhythmias 17 22 26 29 28 0.002
Acute myocardial ischemia 3 1 3 5 8 0.014
Intravenous treatment
Diuretic 93 94 92 90 92 0.085
Inotropic agent 24 20 17 22 17 0.042
Vasodilator 10 15 13 17 17 0.072
Values are % unless otherwise indicated.
CI ¼ conﬁdence interval; IQR ¼ interquartile range.
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1851powerful predictors of prognosis, these ﬁndings are central
to the much better survival of younger patients (see the
following) (4,28). Atrial ﬁbrillation was also signiﬁcantly
less common in younger patients, whether identiﬁed by
medical history at baseline (13% vs. 36% youngest vs. oldest)Figure 1
Kaplan-Meier Mortality Curves in Age Categories for
All-Cause Mortalityor on the baseline electrocardiogram (4% vs. 20%). This
suggests that atrial ﬁbrillation may be an age-related
comorbidity in HF, rather than just a consequence of HF,
especially because severity of HF (associated with the prev-
alence of atrial ﬁbrillation) did not differ greatly across age
groups (6,27,29). Interestingly, the youngest age group had
the lowest prevalence of atrial ﬁbrillation but had the highest
prescribing rate of digoxin. Trial enrollment from 1999
closely followed publication of the Digitalis Investigation
Group trial. Most likely, the aforementioned higher hospi-
talization rates, nonischemic etiology, radiological car-
diomegaly, and worse LVEF and quality of life prompted
physicians to prescribe digoxin more frequently in younger
patients (30).
Although younger patients had a slightly, but signiﬁcantly
more favorable NYHA class proﬁle (i.e., a greater proportion
were in NYHA class II and/or smaller proportion were in
NYHA class III and/or IV) than older participants, they had
strikingly worse HRQL, as assessed by the MLwHF. This
disconnect between NYHA class and MLwHF score is of
interest, and may in part, reﬂect the difference between
a physician-based assessment (NYHA class) and a patient-
reported one (MLwHF). That younger patients reported
worse HRQL has been reported before and likely reﬂects the
Table 5 Kaplan-Meier Mortality Rates for Each Age Category
Age Categories (yrs) 1 Year 2 Years 3 Years
20–39 6 (2–10) 8 (3–13) 12 (6–18)
40–49 5 (4–7) 10 (7–12) 13 (11–16)
50–59 5 (4–6) 9 (8–11) 13 (12–15)
60–69 6 (5–7) 13 (11–14) 19 (18–21)
70 10 (9–11) 21 (20–23) 31 (30–33)
Values are cumulative mortality rate (95% conﬁdence interval).
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1852greater impact of HF symptoms and functional limitation in
an age group that is more active (or desires to be more active)
in meeting the demands of employment and family and/or
social commitments (31,32). Of interest, in connection
with this, younger patients reported more HF-related
symptoms in the past. Although this ﬁnding was not clear
for the current symptoms reported by patients at baseline, the
difference in symptoms between younger and older patients
was also noted during episodes of decompensation after
randomization.Figure 2
Adjusted Hazard Ratios for the Primary Outcome, Secondar
With 60 to 69 Years as the Reference Group
*Adjusted for age, diabetes: insulin-treated, diabetes: other, ejection fraction (per 5% dec
chronic HF more 2 years ago, New York Heart Association classes III and IV, and diastolic b
insulin-treated, diabetes: other, body mass index (per 1 kg/m2 decreased <27.5 kg/m2)
branch block. CV ¼ cardiovascular.The pattern of HF signs also differed strikingly between
younger and older patients. In particular, younger patients
seemed less likely to develop peripheral or pulmonary edema.
Evidence for this was seen in previous and current signs and
in chest radiographic ﬁndings (less frequent pulmonary
edema and effusions) collected at baseline; the same differ-
ences were noted during episodes of decompensation re-
ported after randomization. Intriguingly, less peripheral
edema was noted in younger patients despite a higher
prevalence of an elevated jugular venous pressure and he-
patomegaly in these patients (compared with older patients)
and less pulmonary edema despite a lower LVEF and higher
prevalence of a third heart sound. This suggests, perhaps,
that peripheral and pulmonary endothelial integrity dimin-
ishes with age, leading to increasing capillary “leakiness.”
These ﬁndings also have potential clinical importance for the
recognition of HF in younger patients. HF is unlikely to be
high on the list of differential diagnoses in young patients
with breathlessness, and if the most easily detectable
and commonly recognized signs of HF (i.e., peripheral andy Components and All-Cause Mortality by Age Categories,
rease <45%), previous heart failure (HF) hospitalization, cardiomegaly, diagnosis of
lood pressure. yAdjusted for age, ejection fraction (per 5% decrease<45%), diabetes:
, female, New York Heart Association classes III and IV, current smoker, and bundle
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1853pulmonary edema) are less common in these patients, the
diagnosis may be delayed.
Other clinical and investigative ﬁndings in younger
patients of relevance to patient management were lower
systolic blood pressure, better renal function, and less
frequent bundle branch block.
One particularly unique aspect of the present study was the
prospective collection of information about acute episodes of
decompensation after randomization using a speciﬁcally
designed endpoint form. Nonadherence with medication and
lifestyle measures was reported as a possible contributor toHF
worsening signiﬁcantly more frequently in younger patients
than in older patients. Previous studies reported conﬂicting
results, some supporting ours (33,34), and others not (35).
The recent Get With The Guidelines-Heart Failure
(GWTG-HF) program, which prospectively included 95,127
patients hospitalized with acute HF, reported patients who
were nonadherent (less compliant with medication or dietary
restriction, or both) were younger (nonadherence vs. adher-
ence 64 years vs. 74 years, p< 0.0001) (33). After multivariate
analysis, younger age was independently associated with
nonadherence (odds ratio for the outcome of nonadherence in
younger age [per each year decrease]: 1.022, 95%CI: 1.019 to
1.026; p < 0.001). Younger patients with HF may therefore
merit particular attention in terms of education and other
interventions to improve adherence. In keeping with their
lower prevalence of comorbidity, younger patients were less
likely to have decompensation attributed to myocardial
ischemia or arrhythmias.
Finally, we demonstrated a possible important divergence
between fatal and nonfatal outcomes in younger patients
versus older patients. As expected, younger patients had
a signiﬁcantly lower mortality rate than older patients.
However, there was a suggestion that the youngest patients
(age 20 to 39 years) might have relatively high hospitalization
rates, more in keeping with those ages 60 years than those
ages 40 to 59 years. This divergence was not unexpected given
the lower mortality in the youngest patients that increased the
period at risk of further hospital admission. Coupled with
nonadherence to study drug, cardiac medications, dietary
restriction, and alcohol excess, this might explain the
disconnect of higher HF hospitalization alongside lower
mortality in the youngest patients compared with older
patients. The modest number of patients in the youngest age
group with a wide CI reduced certainty in this ﬁnding.
However, the longer duration of admission experienced by
these patients was consistent with the possibility that they had
more severe HF, as was the greater use of digoxin (despite less
atrial ﬁbrillation) and spironolactone in this age group. Of
additional interest, mortality rates appeared to be relatively
ﬂat across the age range 20 to 59 years, only increasing notably
in patients ages 60 to 69 years and rising again substantially in
those ages 70 years; this 3-step pattern was apparent for
death from cardiovascular causes only and persisted after
adjustment for differences in known prognostic variables that
differed in frequency across the age groups.Study limitations. A number of limitations merit consid-
eration. The number of patients in the youngest age group
was small. This resulted in wider CIs and a greater degree of
uncertainty when interpreting results. Symptoms were
susceptible to recall bias. The etiology of HF and electro-
cardiographic interpretation were reported by individual site
investigators rather than by a core laboratory with stan-
dardized deﬁnitions. Systematic investigation of the etiology
of HF was not mandatory in the study protocol. Serum
albumin was not available for the entire cohort. The study
excluded the sickest young patients who were on the heart
transplant waiting list. This might have altered the mortality
and morbidity outcomes. Conversely, the inclusion and
exclusion criteria of a trial tend to have a greater impact on
the older participants who have more comorbidities (as we
have found here again in CHARM). Therefore, older
participants were likely to be healthier, and consequently, we
believe that the inclusion and exclusion criteria were likely to
have biased the true difference between young and old
patients toward the null, underestimating the difference.
Conclusions
Compared with older patients, younger patients with HF have
a markedly different clinical proﬁle, including a different
pattern of symptoms and signs that could lead to delayed
diagnosis, a greater reduction inHRQL,more hospitalizations
attributed to nonadherence to treatment but better survival,
with relatively low rates of death until the age of 60 years.Reprint requests and correspondence: Dr. Mark C. Petrie,
Scottish National Advanced Heart Failure Service, West of Scot-
land Heart Centre, Golden Jubilee National Hospital,
Agamemnon Street, Clydebank G81 4DY, United Kingdom.
E-mail: Mark.Petrie@glasgow.ac.uk.REFERENCES
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